2022 Revenues ($USD) : $24,998,446,020.00
2022 Revenues (foreign currencies) : DKK kr176,954,000,000
2022 R&D spend : $2,713,672,195.00
2022 Number of Employees : 55,185
Fiscal Year End : 12/31/22
Leader : CEO Lars Fruergaard Jørgensen

Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark, and specializing in diabetes care. It reported full-year 2022 revenue of DKK 176.954 billion ($24.998 billion), reflecting the company's robust performance throughout the year. Sales drivers include the company's GLP-1 diabetes treatments and its diabetes and obesity care segments. As part of its environmental, social, and governance (ESG) initiatives, Novo Nordisk prioritizes sustainability, diversity, and inclusion. The percentage of women in leadership positions increased from 42% to 44% as of Q4 2022, while women in senior leadership positions grew from 35% to 39% during the same period. The company aims to achieve balanced gender representation across all managerial levels by the end of 2025. —BB